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Abstract
We consider a pharmaceutical Research & Development (R & D) pipeline management problem under two sig-
nicant uncertainties: the outcomes of clinical trials and their durations. We present an Approximate Dynamic
Programming (ADP) approach to solve the problem eciently. Given an initial list of potential drug candidates,
ADP derives a policy that suggests the trials to be performed at each decision point and state. For the classical
R&D pipeline planning problem with deterministic trial durations, we compare our ADP approach with other
methods from the literature, and nd that it can nd better solutions more quickly in particular for larger
problem instances. For the case with stochastic trial durations, we compare the ADP algorithm with a myopic
approach and show that the expected net prot obtained by the derived ADP policy is higher (almost 20% for
a 10-drug portfolio).
Keywords: Dynamic Programming, Pharmaceutical R&D Pipeline Management, Heuristics, Approximate
Dynamic Programming, Project Scheduling
1. Introduction
Most pharmaceutical companies develop several molecules and drugs simultaneously. Drug development
(from discovery to market launch) can take up to 15 years, and the average cost of a new drug is about
$1.32 billion of which 50% are spent on clinical trials (Lainez et al., 2012). The candidate drugs go through
four main stages of development: pre-clinical, Phase 1, 2, and 3. The last three stages are highly regulated
and systematized processes to determine the appropriate dosage and whether compounds are eective or not
for humans. The drugs that successfully completed all stages go to the approval process and then to the market
if approved. However, many drug candidates fail during the clinical trials (see Figure 1). On the other hand,
the prots earned from a drug on the market can be quite substantial, e.g. around $ 16 billion per year (Lines,
2012).
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Figure 1: Drug discovery and development timeline (S Raghavendra et al., 2012)
The selection of dierent drug candidates and resource allocation to the related development activities are
known as drug (R & D) pipeline management. Conducting a clinical trial constitutes many activities such as site
recruitment, site monitoring, site retention, patient recruitment, lab activities, and protocol approvals. These
activities involve several critical resources that are usually limited and not easy to expand at short notice. Thus,
although several drug candidates enter the clinical trial stages, not all of them may be conducted at the same
time.
Drug pipeline management requires to make interdependent and dynamic decisions. These include advancing
a drug candidate to the next stage when it successfully passed a clinical phase, or freezing it due to resource and
nancial limitations. There is usually a xed budget to be used for the drug development activities including
clinical trials. Since each trial takes up to 6 years, the decision of allocating resources to any project may result
in a lack of resources for another project during this period. Thus, the decisions taken today aect possible
actions in the future which makes the problem time-dependent.
Drug development activies are aected by several uncertainties. The most signicant uncertainty is observed
in the outcomes of clinical trials. Once the design of a trial has been approved by the regulatory agencies, a
targeted patient sample is recruited. However, there may not be enough patients to recruit or several companies
may be competing for the same pool of patients. Thus, the completion time of a trial may be delayed and cannot
be known in advance. In case portfolio planning decisions are made at xed time intervals, some drugs that
already completed a phase may need to wait until the next decision point. On the other hand, time-to-market
(the time spent in the pipeline) is a crucial factor for the prots to be earned from a drug due to a xed patent
life (Jekunen, 2014). Thus, delaying a candidate should be avoided as much as possible and when trial durations
are stochastic, the timing of decisions within a portfolio planning process may be stochastic as well.
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Drug pipeline management is crucial for pharmaceutical companies considering the associated impact on
prots and costs. Moreover, it is a highly complex process with a dynamic nature involving several uncertain-
ties. However, the industry generally manages the pipelines by ad-hoc policies rather than analytical methods
(Skrepnek et al., 2007). In this paper, we propose a stochastic dynamic programming formulation for the drug
pipeline management problem. Then, we develop an ADP approach based on value iteration that can account
for the complexities of the underlying problem and allows to solve larger portfolio planning problems than other
state-of-art methods which is important since the size of portfolios is expected to increase as the industry moves
toward more personalized medicine. We also compare the ADP approach with a greedy approach applied in
practice that ranks the drug candidates according to ENPV.
The rest of this paper is organized as follows. The next section presents the current literature related
to portfolio planning in pharmaceutical companies. Section 3 presents the stochastic dynamic programming
formulation. The ADP approach is explained in Section 4. Section 5 consists of the computational experiments
and the analysis of the results. Finally, Section 6 summarizes the paper and outlines avenues for future research.
2. Literature Review
Due to the stochastic and dynamic nature of pipeline management problems, a solution should recommend
an action at each possible state and time point. Such a mapping from state to action is called a policy. However,
as the problem size grows, the number of possible states increases quickly, making it harder to obtain the optimal
policy and requiring some approximation tools. The modelling and solution approaches in the literature can
be divided into mathematical programming and simulation-based approaches. To solve the pharmaceutical
portolo planning problem, we propose ADP that combines simulation and dynamic programming to learn an
approximate policy. ADP has been used for many complex operations research problems such as data resource
planning (Li et al., 2014), project scheduling (Li and Womer, 2015), or patient scheduling (Saure et al., 2012;
Lu et al., 2018). To the best of our knowledge, it has not been applied to the pharmaceutical portfolio planning
problem before.
All papers in the literature consider the uncertainty in trial outcomes while trial duration uncertainty is
considered only in few simulation-based papers (Perez-Escobedo et al, 2012; Blau et al., 2004). The most
frequently used performance measure considered for portfolio planning is expected net present value (ENPV),
which takes into account the uncertainty of the outcomes as well as their discounted value with time.
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2.1. Mathematical Programming-based Approaches
The early papers focusing on drug pipeline management use two-stage stochastic programming. In this
framework, the rst stage decisions are drug selection and capacity investments. The uncertainty in trial
outcomes is represented by a large number of scenarios. As the trials are completed, the additional information
is used to make the second-stage decisions that consist of capacity re-allocation or stopping some trials in case
of lack of resources. However, due to the required large number of scenarios, the resulting models are hard to
solve optimally. Thus, several heuristic approaches have been developed to solve real-size instances.
Rotstein et al. (1999) developed a two-stage stochastic programming model for simultaneous drug selection
and capacity planning for a single pharmaceutical production site. Since solving real-size instances to optimality
is computationally burdensome, they used a heuristic cut-o procedure. In this method, the scenarios with
higher probabilities are selected until the overall probability across these scenarios is above a threshold level,
and then the problem is solved in this reduced scenario space. Their computational results indicate that when
the threshold level is around 0.5, the results are satisfactory while the computational eort drops signicantly.
Gatica et al. (2003) proposed to dene four possible outcomes (high, target, low and failure) for clinical trials.
Considering the integer capacity expansion variables as well, the model becomes a large MILP that can be
solved only for very small number of drugs. Thus, the cases solved in this paper only consist of four drugs.
Papageorgiou et al. (2001) developed a deterministic capacity planning model with multi-sites and multi-periods.
The model determines the promising drugs, when and where to produce them and the allocation and expansion
of the capacity. There is no uncertainty in clinical trial outcome and demand. Instead, they consider the transfer
pricing and the taxation framework, as well as manufacturing details, including setup, scale-up, qualication
and manufacturing suite structure.
Patel et al. (2013) considered portfolio planning by incorporating the trial design decisions (sample sizes)
and scheduling of trials simultaneously into the cost and duration parameters. They used integer programming
and considered budget constraints. They calculated the probability of success of a trial by combining frequentist
and Bayesian approaches assuming that a prior distribution is known for ecacy. The decision variables are
binary, indicating whether a trial for a drug is started with a certain type of design at a particular time t. They
also developed a stochastic integer model (Patel and Ankolekar, 2015) that provides solutions for possible Phase
3 outcomes.
Colvin and Maravelias (2008) developed a multi-stage stochastic programming model to nd the trials to
be performed for a given portfolio for each planning period. They reduce the number of scenarios and non-
anticipativity constraints by employing reduction techniques and could solve up to 5 drug instances. Later,
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Colvin and Maravelias (2010) extended their work by developing a novel branch and cut algorithm which
further improves the computational performance: they could solve up to 7 drug instances. Based on the model
presented in this paper, Solak et al. (2010) present a multi-stage stochastic model where the uncertainties are
required investment levels, updated return estimates and nal return levels. They propose a sample average
approximation algorithm to nd the solution.
To solve the same portfolio planning problem, Christian and Cremaschi (2015) proposed three heuristics:
shrinking horizon, multiple two-stage stochastic programming decomposition algorithm and a knapsack decom-
position algorithm. The rst one decomposes the problem into smaller ones that are solved whenever resources
become available. The knapsack approach decomposes the original problem into several knapsack problems,
which are solved at decision points using a rolling horizon procedure. The results obtained for up to 7 drugs
are promising in terms of the optimality gap and computation time. In a more recent paper, Christian and
Cremaschi (2017) extended their knapsack decomposition algorithm by changing the time points where the
knapsack problems are produced. The modied algorithm results in a smaller optimality gap (around 1% for
the 6-drug case) but comparatively larger computation times. They also extended their branch-and-cut algo-
rithm by a new branching method and combine it with the knapsack decompostion approach. Although the
memory requirement of the modied algorithm is much smaller than the exact branch-and-bound algorithm,
the computation times are very large (around 643 hours for the 5 drug case).
Table 1 summarizes the important attributes of the related (both mathematical and simulation-based)
papers. The table shows that the trial outcome is the main uncertainty considered in almost all papers while
trial durations are only studied in two papers (Blau et al., 2004; Perez-Escobedo et al., 2012). Heuristics are
slightly more prevalent than exact methods.
Table 1: A review of the literature on drug portfolio planning
Papers
No. of stages Solution Approach Uncertainties
Single Two Multi Exact Heuristic Simulation Outcome Duration
Rotstein et al. (1999) X X X
Blau et al. (2000) X X X X
Papageorgiou et al. (2001) X X
Gatica et al. (2003) X X X
Blau et al. (2004) X X X X X
Choi et al. (2004) X X X X X
Rajapakse et al. (2005), (2006) X X X
Varma et al. (2008) X X
Zapata et al. (2008) X X X X
Colvin and Maravelias (2008), (2010) X X X
Solak et al. (2010) X X X
Perez-Escobedo et al. (2012) X X X X X
Patel and Ankolekar (2015) X X X
Christian and Cremaschi (2015), (2017) X X X
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A related stream of the literature to R&D pipeline management studies the project scheduling problem.
The project scheduling problem deals with nding the starting times of a number of tasks that constitute a
project and brings a discounted cash ow after all activities are completed successfully. The tasks preserve some
precedence relationship, i.e. need to be performed in order to achieve the prot. Creemers et al. (2010) and
Hermans and Leus (2018) aim to nd the optimum starting time for each task in a project to maximize total
discounted cash ow. They assume that the tasks have exponentially distributed durations. As dierent from
Creemers et al. (2010), Hermans and Leus (2018) allow a task to be interrupted (preemption). They model the
problem as a continuous-time Markov Chain and suggests a near-optimal algorithm.
Wiesemann et al. (2010) study the project scheduling problem but suggest to nd the optimum target
processing time for the activities instead of starting times. In this setting, an activity should start as early as
possible but never before its target processing time. With this change, they formulate the project scheduling
problem as a global optimization problem and solve with branch-and-bound algorithm with instances up to
30 activities. De Reyck and Leus (2008) study the project scheduling problem with deterministic activity
durations, unlimited resources and probability of activity failures. They show that the problem is NP-hard
but small instances can be solved with branch-and-bound to optimality. Dierent from De Reyck and Leus
(2008), Creemers et al. (2009) consider stochastic activity durations and activity failures. They assume that
there are several modules that need to be completed for a project to be successful and bring prot. Each
module contains several activities and at least one of these activities should be completed successfully for the
module to be successful. Similarly, Creemers et al. (2015) develop a stochastic dynamic programming model for
project activities with uncertain task durations and outcomes. Not all modules have precendence relationships.
The problem studied in these papers presents a dierent structure than ours which has several projects and
therefore several dierent prots/nal modules. Finally, Choi et al. (2004) study the resource constrained
project scheduling problem in the presence of task duration, cost and outcome uncertainties. They propose
to overcome the computational complexity by limiting the state space heuristically. Specically, they simulate
dierent scenarios using three simple decision heuristics and only consider the states visited by these heuristics.
They use Bellman iteration to nd the actions for each of these states by using the estimated state values by
the heuristics. However, the Bellman iteration steps as well as combining dierent state spaces of the heuristics
are computationally burdensome. Besides, the heuristics may lead to non-optimum decisions because ignoring
states not visited by any of the heuristics may remove the optimal policy from the search space. In a later
study, Choi et al. (2007) apply Q-learning to expedite the computation of the state transitions while the rest of
the algorithm in Choi et al. (2004) stays the same. They also incorporate the arrival of new projects. Although
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Q-learning is useful as a model-free algorithm, it also requires to consider all state action pairs, instead of states
only. Therefore, it is more ecient when the state transition probabilities are unknown or the set of future
possible states is quite large (Powell, 2011).
2.2. Simulation-based Approaches
Mathematical programming-based approaches usually suer from an exponential increase in the number
of variables as the instance size is increased. Simulation-based methods can solve large size problems more
eciently, but need to be combined with detailed experiments to examine the quality of a solution. This section
summarizes previous research on pharmaceutical portfolio planning by utilizing simulation-based approaches.
We focus on two uncertainties aecting portfolio planning, namely trial outcomes and trial durations. First, we
summarize the studies with deterministic trial durations.
Blau et al. (2000) focus on selection and sequencing of drug candidates. They consider uncertainties in
clinical trial outcomes. First, they compared the candidates in terms of development capital cost, possible sales,
and success probabilities. After a portfolio has been selected based on this comparison, they applied a simple
heuristic utilizing Monte Carlo simulation to sequence the portfolio in the pipeline. They compared dierent
sequences in terms of their ENPVs. However their method cannot explicitly enforce the resource constraints.
Instead, they suggest to keep track of resource constraint violations.
Rajapakse et al. (2005) used Monte Carlo simulation to model the uncertainty in trial outcomes and develop
a decision tool to examine dierent portfolio management strategies. They consider dierent planning aspects
such as resource management, manufacturing activities and clinical trials. Their tool can be used to evaluate
several performance outcomes of a given portfolio (no optimization). They show the practicability of the tool
in a case study. Later, they extended this work, (Rajapakse et al., 2006), by generating an ecient frontier for
ENPV and risk (standard deviation of the NPV distribution) of each possible candidate. Each portfolio in the
ecient frontier is considered as a possible solution.
The trial durations may be aected by uncertainties or resources allocated to them. For resource-dependent
trial durations, Zapata et al. (2008) developed a simulation-optimization based decision tool to aid the resource
management and scheduling of activities within a drug development pipeline. Similarly, Varma et al. (2008)
assume that resource allocations aect activity durations. They developed a decision tool that can be used to
assess the impact of various scheduling and resource allocation policies on several strategic metris such as ENPV,
risk and average time to market. Simulation optimization packages such as Sim-Opt has been utilized for the
research and development pipeline management by Subramanian et al. (2003), Subramanian et al. (2001).
Uncertainty in trial durations may aect the performance of a portfolio signicantly. Thus, several authors
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have considered stochastic trial durations in their modelling. Blau et al. (2004) consider several dependencies
among resources, manufacturing costs, nancial returns and technical successes of drug candidates. They used
simulation to obtain the distribution of NPV for a portfolio and a genetic algorithm to optimize the drug
selection and sequencing. This combined method results in 28% increase in ENPV compared to a bubble chart
approach that visualizes the drug candidates according to their expected revenues and shows the pareto frontier.
However, it is also computationally burdensome; it takes about 60 hours for the algorithm to nd a solution.
Extending the work of Blau et al. (2004), Perez-Escobedo et al. (2012) additionally consider multiple objec-
tives: NPV and risk of money loss. They combined simulation and a genetic algorithm to model the uncertainties
aecting the portfolio planning, such as activity durations and trial outcomes, by using intervals rather than
point-wise estimates.
2.2.1. Literature Gaps and Contribution
Our review shows that there are several gaps in the literature for the drug pipeline management problem:
• Few authors study the case where the trial durations are stochastic. Most of the time, the decisions need
to be taken as soon as information is obtained (such as the completion of a clinical trial). However, trial
durations cannot be known exactly beforehand due to the inherent uncertainties in the patient recruitment
process.
• The stochastic arrival of new candidates into the pipeline is not considered. The authors assume a xed
set of drug candidates throughout the planning horizon.
• The number of drugs considered is at most 10, while the pipeline of top 25 pharma companies range from
66 to 251 drugs with an average of 141 drugs (Informa UK, 2017).
To adress these gaps in the literature, we propose a stochastic dynamic programming model and an ADP
algorithm. The proposed solution framework is exible enough to incorporate the features not considered in
the current literature. Meanwhile, our approach still produces near-optimal policies for the instances up to 10
drugs, within a reasonable solution time, especially as the portfolio size increases.
3. Stochastic Dynamic Programming Formulation
In this section, we present a stochastic dynamic programming framework for the drug pipeline management
problem. We follow the model of Christian & Cremaschi (2015, 2017) that is in line with most of the models
presented in the literature. Later, this model is extended with uncertainty in trial durations. We assume that
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the revenue for a drug is obtained as a lump sum once all corresponding trials have been completed successfully.
In practice, pharmaceutical companies collect drug revenues over a long time horizon. However, this is assumed
to be certain and thus the revenues can be combined into a single net present value. Finally, we do not allow
preemption, i.e. a trial is not stopped before it is completed. The clinical trials are conducted based on a
protocol that has been approved by regulatory agencies beforehand.
Sets:
• The planning horizon is assumed to be nite and divided into discrete time periods (decision points),
represented as t = 1, · · · , T at which the decisions are made. Note that if a trial is still continuing for a
drug candidate, no decision is made for this candidate until the current trial is completed. The duration
between two decision points is assumed to be xed, e.g. 3 months.
• The number of drug candidates in the pipeline is P , while each candidate is represented with p = 1, · · · , P .
• We only consider the drugs in clinical stages that are denoted by s = 1, 2, 3.
Parameters:
• Duration of stage s for drug p: dps.
• Cost of stage s of drug p incurred at the start of the stage: qps.
• Probability to complete stage s of drug p successfully: φps.
• Maximum level of resource 1 available at any time: R1max.
• Maximum level of resource 2 available at any time: R2max.
• Resource 1 and 2 usage at stage s of drug p in every time period: r1ps and r2ps.
• Expected revenue to be obtained from drug p, if completed successfully: mp.
• Late launch penalty rate for drug p due to a shorter patent life: ρp.




• The current status of drug p at time t is denoted by:
fpt =

2, if drug p has completed all stages successfully,
1, if the current stage of drug p has nished with success,
0, if the current stage of drug p is still continuing,
−1, if the current stage of drug p has nished with failure,
−2, if drug p is frozen.
• The current stage of drug p at time t is denoted by ψpt. If the project has not started yet or has failed,
then ψpt = 0.
• The number of periods that have passed since the current stage has started for drug p at time t is denoted
by hpt.
State of the system at time t is denoted by St = [ft,ψt,ht], where ft = {fpt, p = 1, · · · , P} and ψt and ht
are dened similarly.
Uncertainties: Note that the success probabilities are only eective when the drug completes a trial. We
dene φ′pt as the (eective) success probability for drug p at time t. In other words, φ
′
pt shows the success
probability of drug p for its current stage. Note that we need to update the duration passed for a trial. If
hpt + 1 < dp,ψpt ,
hp,t+1 = hp,t + 1, ∀p, t = 1, · · · , T − 1,
otherwise,
hp,t+1 = 0, φ
′
pt = φp,ψpt , ∀p, t = 1, · · · , T − 1.
For the stochastic trial duration case, we dene additional probabilities ζpt(hpt) showing the probability of
trial completion in the next period given that hpt periods have passed for trial t of drug p. This additional
uncertainty increases the number of possible future states, St+1, at each time period.
Decision Variables:
• We dene ypt as 1 if project p is advanced to the next stage at time t, and 0, if it is frozen (put on hold).
If a drug is frozen, it means that the next clinical trial does not start until an advancing decision (if any)
is made in a future period.
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Feasible Actions: The action that can be taken for a drug at time t depends on the status of the drug;
• If the current stage of a drug ended successfully, then,
 If it was the last stage (ψpt = 3), no action is taken, prot occurs and fpt is set to 2.
 Else, the decision maker should either advance the project to the next stage or freeze it.
• If the project was frozen (fpt = −2), again a decision has to be made about advancing or freezing the
project.
• If the current stage is continuing or failed (fpt = 0,−1), or the drug had completed all stages succesfully
(fpt = 2), then no action is taken (ypt = 0).
Note that the set of feasible actions is constrained by the available resources. The set of feasible actions available











p,ψpt , ypt = 0 ∀ p|fpt = 0,−1, 2, i = 1, 2
}
. (1)
This formulation can be extended to consider more complex resource requirements. For example, if the resource
requirement at each time period is dierent, then rip,ψpt can be replaced with r
it
p,ψpt
and the feasibility within
several periods ahead would be considered. This extension is investigated in the computational experiments.
Note that two types of resources are used only for the comparison purposes with Christian and Cremaschi
(2015), in the rest of the experiments a single resource type is assumed.
Update the state after the action:
• If drug p is advanced to the next stage (ypt = 1), then the current stage and the drug status are updated:
ψp,t+1 = ψpt + 1, fp,t+1 = 0.
• Else if the drug is frozen (ypt = 0): ψp,t+1 = ψp,t, fp,t+1 = −2.
• Otherwise (the drug has failed), ψp,t+1 = 0.
Figure 2 presents the possible transitions between dierent drug states. The drug can be in any of 5 possible
states at any time. Depending on the action, the stage of the drug and the transition probabilities, it can move
to any of 5 states. Note that the states where the drug is successful or the trial (and equivalently drug) has
failed are absorbing states. The state of a successful drug does not change as it is completed. After a trial
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success, if that is the last stage, then the system moves into the drug success state. If it is not the last stage,
then it can be either frozen or advanced which correspond to moving into trial continue or drug frozen states.
A continuing trial can continue, fail or become successful depending on the probabilities. A frozen drug can be
advanced and the system moves into trial continue state or kept frozen.
Figure 2: State transition diagram for drug pipeline management problem
One-step Cost Function: We assume that there is no cost of freezing while the cost of advancing is the
lump sum cost of the corresponding stage, incurred at the beginning of that stage. One step cost of action yt




(1− 0.025t)(qp,ψpt+1)ypt, t = 1, · · · , T − 1, (2)
that is linearly depreciated with rate 2.5% for each time period (Christian and Cremaschi (2015)).
Value Function: Note that the cost of clinical trial mainly depends on the sample size of the trial that is
computed by the company based on statistical considerations. Once the trial protocol has been approved by the
regulatory agencies, the company recruits the patients which mostly aects the duration of the trial. Therefore,
the cost of the trial is not dependent on the trial duration but rather the sample size, i.e. we are assuming a
stochastic recruitment rate. If all clinical trials of drug p are completed successfully at time t (ψpt = 3, fpt = 1),
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then the present value of the prot




occurs. Note that the late launch penalty depends on the total time periods that the project has stayed idle.





The objective of dynamic programming formulation is to minimize the ENPV of the planning period. Let's
represent the objective function as V0(S0) which is also labelled as value function of the initial state S0 in t = 0.




Mt(St)− c(yt) + E[Vt+1(St+1|St,yt)]
}
, ∀St, t = 1, · · · , T − 1, (3)
Note that all possible future states St+1 are generated based on the current state St and action yt. Then, the
expected value of each possible future state is multiplied with the probability of that corresponding state which
depends on both probabilities of trial success and the completion, ζpt(hpt) and φ
′
pt, in the stochastic duration
case.
The value obtained at the end of the planning horizon consists of the expected prots from frozen and
continuing projects, shown with mopenp and mcontp and are formulated as


































The late launch penalties ρp and γp ensure that the prots computed for the open projects always have a
smaller expected revenue than completing them within the planning horizon. Therefore, it is penalized to delay
the projects. Note that Christian and Cremaschi (2015) use the following formulations for open and continuing
13
projects:



























p εp, ∀p, (11)
mcontp = rev
cont
p εp, ∀p (12)
that are used when comparing our algorithm with theirs. For both cases, the value at the end of planning
horizon is formulated as







The motivation behind dierent revenue formulations is that we consider the probability of failure in the coming
trials explicitly rather than implicitly as in their formulation. Also note that the prot obtained in the previous
time steps are then added backwards to the the value at the end of the planning horizon.
4. Solution Method: Approximate Dynamic Programming
The portfolio planning problem outlined in the previous section is computationally expensive to solve due
to the large state space. For example, in a small instance with 3 drugs, and at most 6 time periods for a trial,
the state space may be as large as 903 = 729, 000.
Note that there are only two possible actions for a frozen drug or a drug that successfully completes a trial.
Considering that the probability of a successful trial is small, few drugs require an action at any decision point.
Besides, the resource constraint limits the number of drugs that can be advanced at the same time. Thus, we
use enumeration to nd the optimal action at a decision point.
Simulation-based ADP is very suitable to solve large stochastic dynamic programming problems (Powell,
2009). To solve the pharmaceutical portfolio planning model, we develop a simulation-based ADP algorithm
with double-pass (Powell, 2009). We apply both a lookup table and basis function approximation. In this section,
we provide the details of the proposed ADP algorithm with the lookup table approach. A linear programming
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based ADP is not applied since the value function (3) is complex (Powell, 2009). We implement a value iteration
based algorithm instead of policy iteration since the problem has a large state space and a comparatively small
action set (Sun and Li, 2013).
ADP is a forward pass algorithm by default, i.e. the algorithm moves forward in time at each step. However,
the costs or revenues realized in the later time periods should be transferred to the previous time periods. With
the default single pass version, this transfer may take many iterations. To overcome this problem, a double pass
is suggested (Powell, 2007) which employs an additional backward pass updating the value function estimations
by moving backwards in time in the trajectory. Note that most of the revenues are collected towards the end of
the planning horizon (including for unnished projects). Thus, we prefer a double pass, rather than a single-pass
approach, to update the state values at each iteration. In the double-pass approach, at the end of an iteration,
the value of each state in the chain is propagated backward from the last state through to the initial one.
In order to increase the number of explored states, a random feasible action is selected with probability Γ.
Otherwise, the action is selected randomly among the optimum actions computed that have the same optimal
value. However, this strategy may result in suboptimal policies and decreases the exploitation (Powell, 2009).
Therefore, we only apply it for the rst half of the iterations, i.e. for n = 1, · · · , N/2, where n and N denote
the iteration counter and the maximum number of iterations set by the modeller, respectively.
An initial state S0, as well as the probability distributions for trial outcomes are given as the inputs to the
algorithm. As we run the algorithm, each visited state and its approximate value are inserted into a (lookup)
table. At each iteration of the algorithm, we simulate a possible scenario over the entire planning horizon. The
decisions implemented in each scenario are computed based on the Bellman equation (3) and the estimated
values of the states computed in the previous iterations. Next, the algorithm employs a backward pass, i.e.
following the scenario back in time and updating the values of the earlier states. Algorithm 1 shows the pseudo-
code of the ADP algorithm with value iteration, lookup table and double pass. The algorithm is divided into
four main steps. After initialization, the algorithm enters a loop consisting of carrying over the values computed
in the previous iteration, and then executing a forward and backward pass. During the forward pass, it simulates
a scenario and chooses actions based on Bellman's equation or randomly based on some probability in the rst
half of the run. During the backward pass, it updates the state value estimates based on the information gained
during the forward pass. Once the maximum number of iterations has been reached, it returns the computed
values and states, i.e. the lookup table.
The initial state, with all drug candidates frozen, is the same in each iteration, and its value (S01) is initialised
as zero. Based on the probability distributions of trial outcomes, at each iteration n and time t, the outcomes of
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completed trials, and thus the drug status vector fnt , are generated. If n ≤ N/2 and a generated random number
ω ∈ [0, 1] is smaller than Γ, then an action ynt ∈ A is chosen randomly among feasible actions. Otherwise, it nds
the optimum action ynt ∈ A as well as the state value, represented with vnt (Snt ), by using the Bellman equation
(3) and the approximate values stored in the lookup table. If the value of a state required in the calculation
of the selected action has not been visited by the algorithm before, then it is estimated as the summation of
the ENPVs of the continuing projects which is a lower bound. The ENPV of a continuing project is computed
by multiplying the success probabilities of the remaining clinical trials of the project with its discounted prot.
Snt+1 can be computed based on the selected action y
n
t , and the state S
n
t . In other words, for the ongoing
projects in Snt and the advanced drugs y
n
t , a new drug status vector f
n
t+1 is generated based on the success
probabilities. The other state variables are also updated as explained in Section 3. The value stored in the




t ) for n = 1, · · · , N and t = 1, · · · , T .
In each iteration n = 1, · · · , N , after all states in the sample path have been visited, the algorithm goes
backward in time and recursively reects the values of the future states (in the sample path) into vnt for
t = T −1, · · · , 1. If a state Snt is visited for the rst time by the algorithm, then its computed value vnt is directly
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t ) + (1−αn)vnt (Snt ). Since the state values are expected to approach their
exact values through iterations, αn is formulated as a linearly increasing function of n: αn = a + bαn where a
and b are parameters. The linear form is selected because it is simple and also converges eventually (Powell,
2007). Finally, the values stored in the lookup table for all states visited until iteration n are carried over to








t ) for k = 1, · · · , n and t = 1, · · · , T .
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Pseudo-code of the ADP algorithm





1) as 0 for k = 1, · · · , n− 1, n = 1, · · · , N .
for n = 1, 2, · · · , N , do






for t = 1, 2, · · · , T − 1, do
− Generate fnt based on Snt−1.
− Generate a random number ω and,
if n ≤ N/2 and ω ≤ Γ then
Randomly select ynt among the feasible action set A, and compute vnt (Snt ) by using (3).
else
− Find the action ynt and vnt (Snt ) by solving (3) based on the state values stored in the lookup table.
− If a state value does not exist in the lookup table, then its value is assumed to be the sum of ENPVs
of all frozen and continuing projects.
end if
− Update state variables based on the action ynt and Snt : Snt+1 = St+1(Snt ,ynt ).
end for
Backward Pass:
for t = T − 1, · · · , 1 do
− Compute vnt (Snt ) = vnt+1(Snt+1)− c(ynt ), where c(ynt ) is dened as in (2).
if state (Snt ) exists in the lookup table, then




t ) + (1− αn−1)vnt (Snt ),
else




Return all value function approximations (V
N
t , i.e. lookup table) for t = 1, · · · , T .
A high level description of the algorithm can be seen in Figure 3.
4.1. Extension to Base Formulation
The portfolio planning model presented in Section 3 allows us to compare the ADP algorithm with other
solution methods proposed in the literature. However, this formulation still lacks important aspects of the
problem such as emergence of new drug candidates or stochastic trial durations. To incorporate the emergence







Forward Pass: for t=1, …, T
- Generate trial outcomes 
- Either randomly select an action or use Bellman 
  equation to find the optimum action
- Update the state based on the optimum action
Backward Pass: for t=T, …, 1
- Update the previously computed state values with 
  the ones computed in forward iteration
No
Yes
Figure 3: High level owchart of the ADP algorithm
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drug: fpt = −2, ψpt = 0, hpt = 0 with a small probability, 0.1, based on expert opinion. Note that since at most
one drug can be added at each time period, the number of new drugs is nite. Therefore, the drug list can be
initialized with maximum number of possible drugs in the portfolio during the planning horizon, whereas only
really existing drugs are considered.
Another possible extension is to include drug dependencies. Pharmaceutical companies can target one disease
with several drug candidates. In this case, the technical or nancial attributes of these candidates would be
aected by the failure or success of other similar candidates (Blau et al., 2004). If one of the drugs in a similar
group of drugs fails (succeeds) in a clinical stage, then the probability of failure (success) for the other drugs in
the group increases. Also, we assume that if a drug in a group launches successfully, the expected revenues of
the other drug candidates in the same group decrease. A scenario with drug dependencies is investigated in the
computational experiments.
Other possible extensions considered are variable resource requirements during a trial and speeding the trials
by putting more resources. The rst extension requires to update the formulation of feasible actions 1. The
other extension requires to double the action space by dening the resource levels of each continued trial as
decision variables. The applicability of ADP on these extensions is presented in the computational experiments
for a small instance.
4.2. Basis Functions and Value Function Approximation
The lookup table ADP does not guarantee to provide a value for each possible state, even though it covers
most of the state space. Thus, an alternative approach based on basis functions is also implemented which
ensures to provide a value function approximation for all possible states. In this approach, the state values are
approximated by a basis function instead of reading them from a lookup table. Usually, the basis functions are
selected as a linear combination of the state variables and based on trial-and-error (Powell, 2007). To nd a good
basis function, we apply regression on the approximate state values computed by the lookup table approach.
After trial and error, the best t for approximate state values is achieved by:
















2ψptmp, if fpt = −2||1,
0.5ψptmp elseif fpt = 0,
0, otherwise,
and w1 and w2 are the weights of the corresponding basis functions. The second summation in (13) computes
the number of projects that are not completed yet. The values for these weights are updated as the algorithm
runs for each particular instance, i.e. they are dependent on the particular instance. The approximate state
values obtained by the proposed basis function converge to the ones computed by the lookup table approach.
This indicates that this structure can be used to nd an approximate policy (Powell, 2007). The basis function
structure suggests that the expected prot of a drug has a positive eect on advancing that drug. Also, it is
preferred to advance the drug that has completed more phases. Our experiments with dierent instances showed
that the R-square levels and coecients do not dier substantially for dierent instances of the problem.
5. Computational Experiments
The computational experiments consist of three parts. The rst part simply asserts the stability of the policy
derived by ADP. The second part examines the performance of ADP under a variety of problem settings. Because
we are not aware of any other published approach that is capable of handling the complexities considered, we
compare the results to a myopic heuristic often used in industry based on our discussions with industry partners.
For these experiments, we use test instances based on a dataset that is partially collected from industry (BIO
et al., 2016) and shown in Table 8 in the Appendix. Trial durations for Phase 2 & 3 are assumed to take
{x̄ − 1, x̄, x̄ + 1} with equal probabilities, where x̄ is given in Table 8 under the trial duration column. The
durations of Phase 1 are assumed to be deterministic. Maximum available capacities are 15, 6 and 3 for 20,
10 and 5-drug instances, respectively. The nal part compares the performance of ADP with a state-of-the-art
solution method from the literature on simplied problem instances with deterministic trial durations. We
assume that decisions are taken every 3 months and there are 14 time periods.
5.1. The Stability of the Derived ADP Policy
The policy resulting from an ADP run depends on the scenarios generated during the run. Therefore, a
dierent ADP policy may be obtained at every time the algorithm is run. We expect that the policies obtained
from dierent runs would be similar to each other. To validate this assumption, we generate 30 ADP policies
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(from 30 runs) by using the same set-up (1000 iterations). Then, we apply these policies on 1000 randomly
generated pathways and obtain the ENPVs corresponding to each policy for a 5-drug instance.
To investigate the source of variation in ADP runs, we conduct an ANOVA analysis on the ENPV values
obtained by dierent ADP runs. The p-values, shown in Table 2, suggest that the variance is caused by in-
sample simulation variation, while the variation due to dierent ADP policies is not signicant (the second row).
The following results will thus be based on a single policy.
Table 2: ANOVA results for source of variation
Source of Variation F-value P-value F crit
Scenario 6.501 5.4E-275 1.113
Policy 0.538 0.847 1.881
Note that the stability of the ADP algorithm is independent of the particular instance due to this charac-
teristic being inherent to the nature of the algorithm.
5.2. Performance Comparison of ADP Algorithm with a Myopic Approach
In this section, we use the drug pipeline management model with uncertain durations. As there is no
algorithm in the literature to solve the full model dened in Section 3, we resort to a greedy (myopic) approach
that is also applied by pharmaceutical companies in practice (based on expert opinion). In this greedy approach,
the available projects in the pipeline are ordered according to decreasing ratio of expected revenue/resource
requirements over all stages ahead. Then, starting from the top of this list, the projects are advanced until there
are not enough resources left to advance another project.
In this section, we compare the performance of such a greedy approach and our ADP algorithm considering
the uncertainties in trial duration and outcome. We obtain an ADP policy (a lookup table) by running ADP
algorithm for 1000 iterations and apply the myopic approach and the ADP policy on 1000 scenarios. The average
ENPVs and standard errors reported throughout this section are obtained from applying these two algorithms
on these scenarios. Note that when a state does not exist in the lookup table of the ADP policy, we use the
basis function approximation to nd the optimum action (cf. Section 4.2). The average ENPVs obtained by
ADP and myopic approaches, along with standard errors and % improvement of ADP over myopic in terms of
ENPV are presented in Table 3 for 3 dierent instances.
Table 3: Average, ± standard error and % improvement of ENPVs obtained by myopic and ADP policies
20-drug 10-drug 5-drug






Myopic 528 ± 3.26 247 ± 3.24 59 ± 2.52
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The ADP algorithm results in around 13, 21 and 30% larger ENPV than the myopic approach for 20, 10
and 5-drug instances, respectively. These results indicate that as the portfolio size is smaller, the advantage of
ADP increases.
Variable Resource Requirements during a Trial: In this extension, we assume that the resource require-
ments are not xed throughout a clinical trial but vary over time. The formulation that computes the




′ represents the time passed in the current trial of drug p (i.e. for t′ > dp,ψpt , r
it′
p,s = 0), and


















, i = 1, 2, t′ = 1, · · · , T − t, ypt = 0 ∀ p|fpt = 0,−1, 2,
}
,
which checks whether the action is still feasible for the upcoming periods. Since the resource requirements
may change each time period, actions that were not feasible in the previous time period may become
feasible later. Therefore, in the following period, the algorithm needs to check again whether the frozen
drugs can be advanced, if there are any. This leads to a longer computation time.
To examine the algorithm's performance in this extended model, we solve the 5-drug case of Christian
and Cremaschi (2015) (Table 7) assuming that the resource requirements increase by one unit from their
original levels in the 3rd and 4th time periods of a trial and decreases by one unit in the 5th and 6th time
periods. In this case, we have to increase the maximum available resource level of 2nd resource type to 4,
otherwise none of the drugs could be completed. The ENPV changes to 295 ± 5.47, whereas the ENPV
of the original model, solved with the increased maximum resource as the extended one, is 303 ± 5.6,
showing no signicant dierence. The computation time (50 seconds), as well as the policy obtained, do
not show a signicant dierence to the original model. The myopic policy provides a signicantly smaller
ENPV in both cases, as shown in Figure 4.
Choosing Resource Requirements to Speed up Trials: In practice, it is often possible to speed up a trial
by allocating additional resources. This case requires to expand the action space, as the resource level for
each advanced trial becomes a decision variable. For example, a trial can be executed with more resource
use and shorter duration in addition to the default resource use and duration. In this case, there would be 2
resource categories available. Assuming that Xps resource categories are available for stage s of drug p, the
resource category for drug p in period t is dened as xpt ∈ {0, 1, · · · , Xp,ψpt+1}, as the additional decision


























Figure 4: ENPVs obtained by ADP and myopic approach in dierent model extensions
is added to the state space indicating the resource category used for the execution of the current trial of
drug p. The resource levels and trial durations corresponding to each resource category are also dened
as additional parameters: djps and r
j
ps, where j ∈ {1, · · · , Xp,s}, which replace dps and rps in the original
model.
Since the action space is doubled, the computation time of the algorithm is expected to rise. To examine
its performance, we solve this extended model for the 5-drug case of Christian and Cremaschi (2015),
assuming one more resource category for Phase 2 and Phase 3 trials of each drug (the duration of Phase
1 trials are short anyway), in addition to the original levels. The additional resource category reduces
the (original) duration of a trial by two periods with a one unit increase in the resource use. Due to
the increased resource use in Phase 3 trials, we again need to set the maximum available resource to 4.
To compare the result of this extension, we solve the original model again with the increased maximum
available resource. As shown in Figure 4, the ENPV increases to 366 ± 9.4, which is signicantly larger
than the original model, while the computation time increases to 192 seconds. The ADP policy usually
speeds up Phase 3 trial while this option is used much less frequently in Phase 2 trials. The myopic policy
still provides a signicantly smaller ENPV compared to the ADP.
Capacity Tightness: The resource capacity may aect the performance of the solution algorithms. To inves-
tigate the impact of capacity, we solve the 20-drug instance with 10 (low) and 20 (high) units of capacity.
In addition, to emphasize the relevance of resource restriction, the probability of a new drug appearing
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during a time period is set to 0.2 in all runs. When there are new drugs appearing, the capacity usage
becomes important as the resource requirements increase.
Figure 5 shows the ENPVs and their standard errors obtained by the ADP and myopic algorithms in the
standard (base), high and low capacity cases along with the percentage dierence between the ENPVs
obtained by two methods. The results show that ENPV obtained by ADP is higher than that of the
myopic approach by 14% and 18% in high and low capacity cases, respectively, for the standard (base)
portfolio. This indicates that ADP performs even better relative to the myopic approach when the capacity
is tighter.
Portfolio Compositions: A pharmaceutical pipeline may target dierent therapeutic areas such as oncology or
hypertension. Due to large patient populations of some therapeutic areas, corresponding drug candidates
can have comparatively larger resource requirements and expected revenues. On the other hand, stratied
medicines may have comparatively less resource requirements and revenues. These dierent pipeline
compositions may aect the performances of the solution methods. In the current test, we apply ADP
and myopic algorithms for two dierent types of portfolios both with 20 drugs. The rst one (labelled
as `diverse portfolio') includes at least 6 comparatively large projects while the rest are composed from
medium and small size projects. In the second portfolio (labelled as `harmonized portfolio'), the projects





































Figure 5: ENPVs obtained by ADP and myopic approach in dierent available resource and portfolio compositions
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Table 4: ENPVs obtained by ADP and myopic approaches and % improvement of ADP over myopic in dierent decision timing
strategies
ADP Myopic




Fixed (6 months) 500± 16.74 412 ± 14.6
Figure 5 shows the average ENPV ± its standard error for dierent portfolios and capacity levels. The
results indicate that improvement of ADP over the myopic approach is higher as the portfolio gets more
diverse. We also observe that the capacity change has a more signicant impact on the harmonized
portfolio.
Flexible vs. Fixed Decision Intervals: So far, we assumed that the decision-maker takes an action as soon
as a trial has been completed. An alternative assumption is that the decisions are made at xed time
intervals such as every 6 months. However, this strategy may cause drugs to be released later than they
could, which results in less prot. We implement both strategies (exible with 3 months and xed with 6
months intervals) and show ENPVs obtained by ADP and myopic policies for the 20-drug case (standard
portfolio with 15 units of capacity) in Table 4. In other words, the exible approach allows to make
decisions once in 3 month which is much shorter than that in the xed interval setting.
By allowing for exible decision intervals, ENPVs increase by 20% and 22% for ADP and myopic ap-
proaches, respectively. It should be noted that exible decision timings may be burdensome and not very
practical for senior management in the real world. However, due to its signicant eect on ENPV, it should
be considered. Finally, a smaller time period such as 3 months is not computationally more expensive, as
no decision is made in some time periods.
Drug Dependencies: We investigate the eect of drug dependencies on the performance of solution approaches
and assume that the drug candidates are divided into several groups. If the rst one of the drugs in a
group fails (succeeds) in a clinical stage, the probability of failure (success) for the other drugs in the
group increases by 50% for the same stage. Also, once the rst drug in a group launched, the expected
revenues of the other drug candidates in the same group drop by 50%. The increase/decrease rates are
chosen based on expert opinion.
We divide the drugs into the following groups: {1, 2}, {3, 4, 5}, {6, 7, 8, 9, 10}, {11, 12, 13, 14, 15,
16}, and {17, 18, 19, 20}. To investigate the eects of two types of dependencies (success probability and
revenues) separately, we present the ENPVs for three cases: (i) without any dependencies, (ii) with success
probability dependencies only, and (iii) with both success and revenue dependencies together. Table 5
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shows the average and standard error of ENPVs obtained by ADP and myopic approaches as well as the
percentage improvement between those averages for three cases.
Table 5: Eect of success probability and revenue dependencies on ENPVs obtained by ADP and myopic approaches
No dependency ADP 601 ± 19
13%
Myopic 528 ± 16.8
Probability dependency ADP 560 ± 36
13 %
Myopic 492± 28
Both dependencies ADP 505 ± 41.2
17 %
Myopic 431 ± 29.7
When there is only the success probability dependency, ENPVs obtained by myopic and ADP policies
drop by around 7%. The prots drop by around 19% for ADP policy and 22% for the myopic policy when
both dependencies are present. The results indicate that ADP can handle drug dependencies better than
the myopic approach.
5.3. Performance Comparison of the ADP Algorithm with Other Approaches from Literature
The main motivation behind the experiments of this section is to show that the proposed ADP algorithm
can be used to solve larger problems than the methods proposed in the literature, and still within acceptable
computation times. For this purpose, we select Christian and Cremaschi (2015) as the benchmark study. It is
a recent paper focusing on pharmaceutical pipeline management and also with the biggest instance (10 drugs)
solved so far, therefore considered as state-of-the-art. We used the same modelling assumptions and dataset
as Christian and Cremaschi (2015) which is replicated in Table 7 in the Appendix for 10 drugs. For 3 and
5-drug instances, we used the information in this table for the rst 3 and 5 drugs, respectively. The 20-drug
instance comprises of two copies of 10-drug instance shown in Table 7. Similarly, the 40-drug instance comprises
of the four copies of the 10-drug instance. To investigate the eect of the number of iterations, we run the
ADP algorithm for 200 and 1000 iterations for each instance. The exact solutions reported in Christian and
Cremaschi (2015), are shown in Table 6 for dierent numbers of drugs. They have used CPLEX to nd the exact
solutions of the dynamic model. The table also presents the computation times of the (Knapsack) algorithm
proposed therein and obtained on our computers using the code kindly provided by the authors. Note that the
40 and 20-drug instances are not solved in Christian and Cremaschi (2015), probably due to the computational
intractability.
We also report the ENPV values in terms of mean ± standard error obtained by ADP algorithm over 20
separate tests with 1000 scenarios in each run. The results indicate that the ADP algorithm results in reasonable
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Table 6: Computational performance of the ADP algorithm and the benchmark solution method for dierent number of iterations
and instances
Instance Sol. Method No. of iterations Solver time (sec.) ENPV Optimal ENPV
3-drug
ADP
200 1.27 116 ± 0.75
118.91000 19 118.31 ± 0.75
C&C (2015) - <1 118.9
5-drug
ADP
200 3.66 208 ± 1.3
208.31000 43.87 207.63 ± 1.3
C&C (2015) - 1 204.3
10-drug
ADP
200 29.9 372 ± 2.25
-1000 526 441 ± 2.25
C&C (2015) - 1296 406
20-drug ADP
200 109 809 ± 5.73
1000 2254 911 ± 6.37 -
40-drug ADP
200 3.5 hrs 1866 ± 13.49
1000 20 hrs 2186 ± 15.45 -
computation times across all instances and higher ENPV's than the Knapsack algorithm for instances except the
3-drug instance where the dierence is not statistically signicant in 1000 iterations. Although the computation
time is 20 hours for the 40-drug instance, consider that this policy is generated for more than a 5-year planning
horizon and it may be reduced by using faster computers and a dierent programming language. Also note that
Knapsack algorithm has been coded in Python whereas the ADP algorithm is coded in Matlab. Therefore, the
comparison of computation times is only indicative. All computational experiments are carried out on a PC
with Windows 10 Enterprise operating system, CPU 4GHz Intel Core i7 and 32GB of RAM.
Finally, we also tested the algorithm proposed in Choi et al. (2004) on the 5-drug case. This algorithm needs
heuristics to determine the reachable states. Because our problem setting is somewhat dierent from theirs, we
added our myopic heuristic to their set of heuristics. Still, the algorithm only reached an ENPV of 191.15 (8%
from optimum) and required signicantly longer running times with 1000 iterations for heuristics.
6. Conclusion
Eective drug pipeline management is crucial for the performance of a pharmaceutical company. However,
it is a complex task due to substantial uncertainties and the dynamic nature of the problem. In this paper, we
present a new solution approach to the pipeline management problem as well as model some unexplored features
such as uncertain trial durations and expansion of the pipeline. With the proposed ADP solution approach, we
are able to solve problems of size larger than what has been solved in the literature before, within reasonable
computational times. ADP provides comparable performance to the state-of-art methods for smaller simple
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instances.
We compare the performances of ADP and a myopic heuristic on more complex problems involving uncertain
trial durations, new drugs appearing, and dependencies between drugs. Our computational experiments show
that ADP provides at least 10% increase in ENPV compared to the myopic heuristic. The relative advantage
of ADP increases as the portfolio size gets smaller. We also investigate the impact of several technical factors
such as the level of capacity, dierent portfolio structures, timing of decisions and drug dependencies on the
performance of ADP. These experiments reveal that ADP provides a fairly robust performance against changes
in the environmental factors in terms of its advantage over the myopic heuristic.
Future studies can consider more complexities regarding the problem such as the outsourcing the execution
of trials as an additional decision. Another possible extension is considering a parallel companion diagnostic
development process along with the drug development. A successful companion diagnostic development could
decrease the cost and duration of the trials.
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7. Appendix
Table 7: Data obtained from (Christian and Cremaschi, 2015) for comparison purposes
Duration Probability




P1 P2 P3 P1 P2 P3 P1 P2 P3 P1 P2 P3 P1 P2 P3
1 2 2 6 0.3 0.5 0.8 10 90 220 1 1 2 1 2 3 3100 22 19.2
2 2 4 4 0.4 0.6 0.8 10 80 200 1 2 2 1 1 3 3250 28 19.6
3 2 2 6 0.3 0.6 0.9 10 90 180 1 1 2 1 1 3 3300 26 20
4 2 4 4 0.4 0.6 0.8 10 100 170 1 1 2 1 2 3 3000 24 19.4
5 2 4 6 0.35 0.5 0.9 10 70 210 1 1 2 1 1 3 3150 24 19.6
6 2 4 6 0.45 0.45 0.8 10 85 195 1 2 2 2 1 3 3050 25 19
7 2 2 6 0.45 0.55 0.85 10 95 180 1 1 2 1 2 3 3200 27 19.7
8 2 2 6 0.4 0.6 0.75 20 70 210 1 1 2 1 2 3 3100 22 19.6
9 2 4 4 0.35 0.55 0.8 10 80 195 1 2 2 1 1 3 3200 24 19.4
10 2 2 6 0.25 0.6 0.8 20 80 200 1 1 2 1 1 3 3350 25 19.2
Note: The 20-drug instance is a combination of two 10-drug instance data together.
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Table 8: Hypothetical data used for simulation experiments (standard portfolio)
Duration Probability Trial cost Resource
Revenue γ ρDrugs P1 P2 P3 P1 P2 P3 P1 P2 P3 P1 P2 P3
1 2 2 4 0.62 0.3 0.6 10 100 220 1 1 2 2870 22 19.2
2 1 2 3 0.7 0.3 0.7 10 50 150 0.5 1 2 1200 28 19.6
3 2 4 6 0.6 0.3 0.5 10 130 270 1 2 3 3800 26 20
4 2 4 4 0.6 0.3 0.5 10 70 130 1 2 3 1600 24 19.4
5 2 2 6 0.7 0.3 0.7 10 100 200 1 2 3 2860 24 19.6
6 2 2 4 0.65 0.28 0.5 10 100 220 1 1 2 2870 25 19
7 1 2 3 0.6 0.32 0.6 10 80 200 1 2 2 2500 27 19.7
8 2 2 4 0.6 0.31 0.7 10 70 210 1 1 2 1500 22 19.6
9 1 2 3 0.62 0.32 0.5 10 70 210 1 2 3 2720 24 19.4
10 2 4 6 0.7 0.35 0.5 10 100 220 1 2 3 2000 25 19.2
11 2 4 4 0.6 0.3 0.6 10 50 150 1 1 2 2870 22 19.2
12 2 2 6 0.6 0.3 0.7 10 130 270 1 2 2 2500 28 19.2
13 2 2 4 0.7 0.3 0.5 10 70 210 1 1 2 2000 26 20
14 1 2 3 0.65 0.3 0.5 10 100 220 1 2 3 2720 24 19.4
15 2 2 4 0.6 0.3 0.6 10 50 150 1 2 3 2860 24 19.6
16 1 2 3 0.6 0.3 0.6 10 70 180 1 2 2 2700 25 19
17 2 4 6 0.6 0.3 0.6 10 130 270 1 2 2 2780 27 19.7
18 2 4 4 0.65 0.3 0.6 10 100 270 1 2.5 5 8500 22 19.6
19 2 2 6 0.65 0.3 0.6 10 100 170 1 2.5 5 8500 24 19.4
20 2 2 4 0.65 0.3 0.6 10 70 210 1 2.5 5 8500 25 19.2
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